Thyroid dyshormonogenesis comprises a group of conditions, generally of genetic origin, characterized by an intrinsic defect in one or more steps of thyroid hormone biosynthesis, involving thyroxine (T4) and triiodothyronine (T3), in a thyroid gland that is often eutopic. The most typical clinical outcome is primary hypothyroidism of variable severity, frequently associated with goiter due to chronic stimulation by thyroid-stimulating hormone (TSH). In clinical practice, dyshormonogenesis represents an important cause of “non-dysgenetic” congenital hypothyroidism, with phenotypes ranging from severe neonatal hypothyroidism to mild or later-onset forms, sometimes detected because of thyroid enlargement or incidental biochemical abnormalities.
Its clinical relevance derives from the fact that a biosynthetic defect may already be present during fetal life and, unless recognized and treated early, may lead to adverse neurocognitive outcomes. Moreover, certain specific defects, such as those involving iodide transport or organification, are associated with characteristic functional markers and have implications for family investigations and prognosis.
Thyroid dyshormonogenesis belongs to the spectrum of primary congenital hypothyroidism and accounts for a smaller proportion of cases identified by neonatal screening programs than thyroid dysgenesis. Nevertheless, it is clinically relevant because the thyroid gland is usually normally located, often enlarged, and associated with a greater likelihood of familial recurrence. The observed frequency depends on the screening strategy used, whether TSH-based, T4-based, or combined, on the adopted cutoffs, and on the ability to identify mild or transient forms, including those associated with biallelic variants or combinations of variants in different genes.
The principal “risk factor” is a family history of congenital hypothyroidism, childhood goiter, or the need for early replacement therapy, particularly when the pattern suggests autosomal recessive inheritance. In this setting, consanguinity and membership in populations with a founder effect increase the likelihood of enzymatic or transport defects. However, dyshormonogenesis may also occur in families without known previous cases because of unrecognized rare variants, variable penetrance, or mild phenotypes in affected individuals.
Clinical and biological determinants suggesting dyshormonogenesis include the presence of a eutopic thyroid gland on ultrasonography, possible goiter already evident during the neonatal period or childhood, and biochemical profiles consistent with specific defects. Examples include a discrepancy between elevated TSH and partial preservation of free thyroxine (FT4) in partial forms, or increased radioiodine uptake patterns on functional investigations. From an environmental perspective, iodine intake and nutritional status do not cause dyshormonogenesis, but they may modulate its phenotype. In partial defects, adequate iodine availability may attenuate hypothyroidism, whereas iodine deficiency or excess may reveal or aggravate the dysfunction.
An important epidemiological development is the increasing identification of later-onset or “borderline” forms through the use of high-throughput genetic methods. This has broadened the clinical concept from a “severe neonatal defect” to a continuous spectrum that includes subclinical hypothyroidism, progressive goiter, and the need for reassessment over time to distinguish permanent conditions from transient or partially compensated forms.
Thyroid dyshormonogenesis is caused by abnormalities in proteins involved in specific steps of T4 and T3 synthesis. Under physiological conditions, iodide is taken up at the basolateral pole of the thyrocyte through the sodium-iodide symporter, transported toward the colloid, oxidized, and organified onto tyrosine residues of thyroglobulin. The iodinated residues are then coupled to form T4 and T3, which are subsequently released through thyroglobulin proteolysis. The biosynthetic pathway also includes hydrogen peroxide-generating systems and mechanisms that recycle iodine from iodotyrosines, all of which may be affected by specific defects.
Etiological causes include pathogenic variants in genes such as TPO, encoding thyroid peroxidase, TG, encoding thyroglobulin, SLC5A5, encoding the sodium-iodide symporter (NIS), SLC26A4, encoding pendrin, DUOX2 and DUOXA2, encoding the dual oxidase system and its activator, and IYD, encoding iodotyrosine deiodinase, which is involved in iodine recycling. The phenotypic presentation reflects the point in the pathway at which the obstruction occurs. Uptake defects reduce iodide entry into the cell, organification defects prevent effective iodination of thyroglobulin, coupling and thyroglobulin maturation defects impair hormone formation and storage, while recycling defects increase iodine loss and reduce the overall efficiency of the system.
The central pathophysiological mechanism is an increase in TSH as a compensatory response to insufficient T4 and T3 production. TSH exerts a strong trophic stimulus, promoting follicular hyperplasia and hypertrophy and causing progressive goiter when the defect persists. In more complete defects, hormone production is already insufficient during fetal and neonatal life, resulting in marked hypothyroidism. In partial defects, by contrast, synthesis may be adequate under basal conditions but insufficient during periods of increased demand or changes in iodine availability, producing fluctuating biochemical abnormalities and later clinical presentations.
A distinctive feature of many forms of dyshormonogenesis is that the thyroid gland is normally located and anatomically present but is unable to complete hormone production efficiently. This explains why, unlike thyroid dysgenesis, the gland may be enlarged and metabolically overactive, particularly on investigations using iodinated tracers, without producing an adequate hormonal output. The discrepancy between uptake activity and effective hormone production therefore becomes an important pathophysiological clue when selecting targeted investigations.
In certain specific conditions, dyshormonogenesis is associated with extrathyroidal manifestations. The prototypical example is the spectrum associated with SLC26A4, in which defective anion transport may be accompanied by sensorineural hearing loss and inner ear abnormalities. This makes an integrated assessment that is not restricted to thyroid findings essential. More generally, identifying the impaired biochemical step helps clinicians interpret functional tests correctly, predict the progression of goiter, and plan genetic investigations rationally.
The clinical presentation of thyroid dyshormonogenesis depends on the age at onset, the severity of the defect, and the timeliness of diagnosis through neonatal screening. In more severe congenital forms, signs may emerge during the first weeks of life, although the condition is often identified before the clinical picture becomes overt through the detection of elevated TSH and reduced FT4. When screening is unavailable or the defect is partial, onset may occur later and present during childhood with impaired linear growth, relative weight gain, reduced activity, constipation, and signs of hypothyroidism of variable severity.
In the neonatal history, untreated hypothyroidism may be associated with excessive sleepiness, feeding difficulties, prolonged jaundice, and a hoarse cry, although these findings are nonspecific and may be absent. During childhood, parents may report poor height growth, fatigability, reduced cold tolerance, and learning difficulties. In adolescent girls, menstrual irregularities and delayed pubertal progression may occur when hypothyroidism is significant and prolonged.
On physical examination, a finding suggestive of dyshormonogenesis is goiter in a patient with primary hypothyroidism, particularly when the thyroid gland is normally located and enlargement is progressive. Goiter may already be present at birth or develop over time, depending on the degree and duration of TSH stimulation. In more advanced cases, dry skin, relative bradycardia, delayed deep tendon reflexes, and myxedema may occur, although these signs are generally more typical of undiagnosed or inadequately treated hypothyroidism.
A clinically relevant category includes forms with a “mixed” or nonlinear presentation. Some variants, particularly in genes such as DUOX2, may be associated with transient abnormalities or partial recovery of thyroid function over time, requiring scheduled reassessment. In other cases, patients may maintain FT4 relatively close to the lower reference limit despite persistently elevated TSH. This situation requires careful interpretation because the main concern is not only the current symptom burden but also the potential effects on growth, neurocognitive development, and goiter progression.
When dyshormonogenesis is part of a syndromic spectrum, the clinical picture may include extrathyroidal manifestations. In the presence of suspected hearing impairment or a family history of hearing loss, an association with transport defects such as those related to SLC26A4 should be considered early because it modifies the diagnostic pathway and requires a multidisciplinary approach.
Thyroid dyshormonogenesis is typically suspected in three clinical scenarios. The first is a positive neonatal screening result for congenital hypothyroidism with a eutopic thyroid gland detected by ultrasonography or scintigraphy, particularly when gland volume is normal or increased and TSH is markedly elevated. In this context, the presence of the gland in its normal location shifts attention from a developmental abnormality to a functional defect in hormone biosynthesis.
The second scenario involves a child or adolescent with goiter associated with primary hypothyroidism or persistent subclinical hypothyroidism, in the absence of convincing evidence of autoimmune thyroiditis, such as negative antibodies or an atypical ultrasonographic pattern. In these cases, TSH-driven goiter may represent the anatomical manifestation of a biosynthetic defect that the body attempts to compensate for by increasing thyroid mass.
The third scenario is familial recurrence. Recurrent congenital hypothyroidism, childhood goiter, or the need for early replacement therapy among siblings or close relatives, particularly with a pattern compatible with autosomal recessive inheritance, makes dyshormonogenesis a priority diagnosis. Suspicion increases further when the history includes consanguinity or when family members have mild, undiagnosed phenotypes, such as slightly elevated TSH or adult-onset goiter.
Clinical and instrumental clues suggesting defects in specific steps should also be considered. For example, high radioiodine uptake with inefficient hormone production suggests an organification or coupling defect, whereas reduced uptake may indicate an iodide transport defect. When extrathyroidal signs such as hearing loss coexist, the differential diagnosis should include disorders caused by anion transport defects, with implications for inner ear assessment and genetic counseling.
Overall, dyshormonogenesis should be suspected when primary hypothyroidism, particularly congenital or pediatric, is associated with a eutopic thyroid gland and goiter, or when the family history suggests an inherited defect of thyroid hormone biosynthesis, even in the absence of overt symptoms.
The diagnosis of thyroid dyshormonogenesis requires a sequential pathway that begins with biochemical confirmation of hypothyroidism and proceeds to etiological characterization through imaging and targeted functional tests, followed by genetic testing when indicated. The first step, particularly after neonatal screening, is confirmation through serum measurement of TSH and FT4, which determines severity and allows replacement therapy to be initiated without delay. In congenital forms, the practical objective is to start treatment rapidly to protect neurocognitive development. Etiological investigations may proceed in parallel or at a later stage, provided that they do not delay therapy.
The second step is morphological and topographic assessment of the thyroid gland. Ultrasonography documents location, volume, echotexture, and vascularity, distinguishing a eutopic gland from thyroid dysgenesis and assessing any goiter. Scintigraphy with appropriate tracers allows estimation of uptake and recognition of suggestive patterns. Increased uptake in a eutopic gland points toward a biosynthetic defect occurring downstream of iodide uptake, whereas reduced uptake may indicate a transport defect or another condition that impairs uptake.
When the thyroid gland is eutopic and uptake is preserved, functional tests may help localize the defect. The perchlorate discharge test has historically been used to identify an organification defect. After administration of radioiodine, perchlorate causes the release of iodide that has not been organified. A significant loss of tracer is consistent with inefficient organification. This test requires specific expertise, access to nuclear medicine techniques, and careful patient selection, but it remains conceptually useful for distinguishing organification defects from other abnormalities of the biosynthetic pathway.
Another diagnostic element is measurement of thyroglobulin. In the presence of a eutopic thyroid gland, thyroglobulin may be very low in defects involving TG, whereas it may be elevated or normal in other defects. Interpretation must take age, the degree of TSH stimulation, and the clinical context into account. In selected cases, measurement of precursors and indirect markers of hormone synthesis, integrated with imaging and longitudinal findings, may further support the etiological hypothesis.
Genetic testing has become a central diagnostic tool, particularly when etiological characterization affects family counseling and long-term management. Targeted panels or sequencing of genes involved in thyroid hormone synthesis may identify variants in TPO, TG, SLC5A5, SLC26A4, DUOX2, DUOXA2, and IYD, among others. Testing is particularly indicated in the presence of familial recurrence, significant goiter, a persistent phenotype, or suspected syndromic associations. The differential diagnosis should also include autoimmune thyroiditis, thyroid dysgenesis, transient conditions related to iodine exposure, and central hypothyroidism, which can be distinguished by the TSH and FT4 pattern and the clinical context.
Thyroid dyshormonogenesis can be classified functionally according to the predominantly impaired biosynthetic step because this approach integrates pathophysiology, diagnostic testing, and clinical presentation. The first group includes defects of iodide uptake, in which iodide entry into the thyrocyte is inefficient. In these cases, scintigraphic uptake may be reduced, while the degree of goiter may vary and is often influenced by iodine intake and residual transport activity.
A second group includes defects of organification and of the generation of the oxidizing substrate required for iodination, particularly those involving TPO or the DUOX2/DUOXA2 system. These conditions may present with increased iodide uptake but reduced hormone production, elevated TSH, and frequent goiter. Their severity ranges from severe neonatal disease to milder forms, with the possibility of transient dysfunction or improvement in some variants. Classification according to stability over time may therefore also be clinically useful.
A third group includes thyroglobulin defects, which alter the protein scaffold on which iodination and coupling occur. These forms frequently present with goiter and hypothyroidism of variable severity. Serum thyroglobulin may provide useful clues, but confirmation requires integration of clinical, biochemical, and genetic data. A fourth group includes defects of apical transport and ionic balance within the follicular compartment, including disorders associated with SLC26A4, in which extrathyroidal manifestations may coexist and make a syndromic classification clinically relevant.
From the perspective of clinical severity, complete and partial forms can be distinguished. In complete forms, hypothyroidism is marked and permanent and requires stable replacement therapy. In partial forms, residual hormone production may be sufficient to limit biochemical severity but insufficient to normalize TSH or prevent goiter and long-term consequences. Some forms may also behave in a transient or age-dependent manner, particularly when the genetic background permits partial functional recovery or when environmental factors modify iodine availability.
Finally, a practical pediatric classification distinguishes conditions that are clearly permanent from those that may be transient, with reassessment planned at an appropriate age. This distinction is clinically important because it determines treatment duration, follow-up intensity, and the family counseling pathway.
Treatment of thyroid dyshormonogenesis is based on levothyroxine replacement therapy, with the aims of rapidly normalizing FT4 and maintaining TSH within the age-appropriate range, thereby preventing neurocognitive impairment and limiting the trophic stimulation responsible for goiter. During the neonatal period, prompt initiation of levothyroxine is the principal determinant of long-term outcome. Once hypothyroidism has been confirmed, treatment must therefore not be delayed by etiological investigations, which may continue in parallel within a structured diagnostic pathway.
Dose titration must be individualized and guided by serial FT4 and TSH measurements. Pediatric biochemical targets and normalization time frames differ from those used in adults, and growth and development require adequate and stable replacement. Prevention of overtreatment is also important because excessive thyroid hormone exposure during childhood may affect growth rate, behavior, and skeletal maturation. Conversely, undertreatment maintains the risk of neurocognitive impairment and promotes goiter progression.
In patients with goiter, normalization of TSH also represents a morphological treatment strategy. Reducing trophic stimulation may stabilize or decrease thyroid volume. However, some goiters may persist because of structural remodeling, particularly when diagnosis is delayed or TSH stimulation has been prolonged. In these cases, in addition to optimizing replacement therapy, follow-up ultrasonography helps assess changes in thyroid volume and the possible development of nodules.
Management must include attention to factors that interfere with levothyroxine absorption, including certain foods, iron- or calcium-containing supplements, and medicines that bind thyroid hormone. During infancy and childhood, administration technique and family adherence are crucial. Caregiver education is an integral part of treatment and should be reassessed over time, particularly during critical transitions such as weaning and school entry.
When dyshormonogenesis is associated with extrathyroidal manifestations, treatment remains based on thyroid hormone replacement for the thyroid component but requires a multidisciplinary approach. When hearing impairment is suspected, for example, audiological assessment is not an optional investigation but part of comprehensive care. In patients with a defined genetic diagnosis, genetic counseling also allows discussion of recurrence risk, family screening, and reproductive options, integrating endocrine treatment with a precision medicine approach.
Follow-up in thyroid dyshormonogenesis has specific objectives that extend beyond biochemical monitoring alone. During the neonatal period and the first year of life, the priority is to bring FT4 rapidly into the target range and stabilize TSH, with frequent testing because levothyroxine requirements change rapidly with growth and maturation. Thereafter, the frequency of monitoring may be adjusted but should remain sufficiently regular to detect changes associated with growth, puberty, weight variation, and treatment adherence.
Clinical monitoring includes height growth, weight, psychomotor development, school performance, and general well-being. Assessment of bone maturation may be indicated when hormonal control has been unstable or when signs of accelerated or delayed growth are present. Symptoms must be interpreted cautiously because many pediatric manifestations are nonspecific. Integration of clinical and biochemical findings is therefore essential to avoid both undertreatment and excessive replacement.
In patients with goiter, periodic thyroid ultrasonography has a practical role. It documents changes in gland volume and echotexture, allows early identification of nodular areas, and distinguishes diffuse goiter from patterns suggesting concurrent disease. Persistent goiter despite well-controlled TSH requires comprehensive reassessment because it may reflect structural remodeling, variable adherence, or local factors independent of trophic stimulation.
A key aspect of follow-up is reassessment of possible transience in selected forms. Some genetic variants, particularly those causing partial defects, may allow sufficient residual function to develop over time. However, any trial of controlled treatment withdrawal must be planned at an appropriate age and under safe conditions, with close monitoring of TSH and FT4 and clearly defined clinical criteria for restarting therapy. This approach avoids both unnecessarily prolonged treatment and premature withdrawal that may expose the patient to unrecognized hypothyroidism.
When a genetic diagnosis has been established, follow-up may include recommendations for family screening and management of associated comorbidities. Coordination among the pediatric endocrinologist, clinical geneticist, and other specialists when required ensures a coherent care pathway and reduces the risk of overlooking clinically relevant extrathyroidal manifestations.
The prognosis of thyroid dyshormonogenesis is generally favorable when diagnosis is early and replacement therapy is adequate and stable. The principal determinant of neurocognitive outcome is the speed with which the availability of thyroid hormones is normalized after birth because T4 and T3 are essential for myelination, neuronal maturation, and the development of cognitive functions. With timely treatment and good TSH control, many patients achieve growth and development comparable to those of their peers.
The most typical complication, particularly in patients diagnosed late or with suboptimal biochemical control, is progressive goiter. Chronic TSH stimulation may cause persistent enlargement and, over time, structural heterogeneity with possible nodule formation. This does not automatically imply neoplastic transformation, but it requires clinical and ultrasonographic surveillance, particularly when thyroid volume is substantial or nodules develop. In most cases, prevention of this complication depends on maintaining TSH within the target range and avoiding prolonged periods of elevation.
Another area of potential complications concerns treatment instability. During childhood, changes in adherence, administration errors, and absorption interference may produce periods of undertreatment or overtreatment. Undertreatment may lead to impaired growth, fatigue, and reduced school performance, whereas overtreatment may promote autonomic symptoms, sleep disturbances, and excessively advanced skeletal maturation. Prognosis therefore depends not only on the initial diagnosis but also on the quality of follow-up and continuous treatment education.
In forms associated with extrathyroidal manifestations, overall prognosis also depends on the management of these components. When hearing is affected, early identification and rehabilitative interventions are crucial for language development and school integration. More generally, etiological characterization, when possible, is not merely theoretical but provides a means of stratifying risks, planning surveillance, and optimizing long-term care.
Overall, thyroid dyshormonogenesis is a chronic condition that can be managed effectively. With appropriate replacement therapy, structured monitoring, and attention to the specific characteristics of the biosynthetic defect, most patients can maintain a good quality of life and normal auxological and functional development.